LENZ vs. IPHA, ELEV, IVVD, CHRS, GLUE, SCLX, CGEN, INMB, FENC, and CMPX
Should you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include Innate Pharma (IPHA), Elevation Oncology (ELEV), Invivyd (IVVD), Coherus BioSciences (CHRS), Monte Rosa Therapeutics (GLUE), Scilex (SCLX), Compugen (CGEN), INmune Bio (INMB), Fennec Pharmaceuticals (FENC), and Compass Therapeutics (CMPX). These companies are all part of the "biological products, except diagnostic" industry.
Innate Pharma (NASDAQ:IPHA) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.
Innate Pharma has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.
Innate Pharma received 34 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 54.93% of users gave Innate Pharma an outperform vote.
0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 38.4% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Innate Pharma has higher revenue and earnings than LENZ Therapeutics.
LENZ Therapeutics' return on equity of 0.00% beat Innate Pharma's return on equity.
Innate Pharma presently has a consensus price target of $9.75, suggesting a potential upside of 255.84%. LENZ Therapeutics has a consensus price target of $31.33, suggesting a potential upside of 104.93%. Given LENZ Therapeutics' higher probable upside, research analysts plainly believe Innate Pharma is more favorable than LENZ Therapeutics.
In the previous week, Innate Pharma had 1 more articles in the media than LENZ Therapeutics. MarketBeat recorded 3 mentions for Innate Pharma and 2 mentions for LENZ Therapeutics. Innate Pharma's average media sentiment score of 0.93 beat LENZ Therapeutics' score of 0.72 indicating that LENZ Therapeutics is being referred to more favorably in the news media.
Summary
Innate Pharma beats LENZ Therapeutics on 8 of the 13 factors compared between the two stocks.
Get LENZ Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LENZ Therapeutics Competitors List
Related Companies and Tools
